pyrazine-2-diazohydroxide (diazohydroxide)

10/15/1993 - "Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors."
12/01/1987 - "The synthesis, chemical stability and anti-tumor activity of pyrazine diazohydroxide, sodium salt, a compound that has been selected for development to clinical trials, are described. "
07/01/2011 - "(AIC is formed in amounts equimolar to the active alkylating moiety, methane diazohydroxide, which is undetectable by known validated assays.) Patients with advanced solid tumors received intravenous dacarbazine 1,000 mg/m(2) on day 1 of a 21-day cycle to evaluate the PK of dacarbazine alone. "
12/01/1987 - "Synthesis, chemical stability and pre-clinical anti-tumor activity of pyrazine diazohydroxide, sodium salt (NSC-361456)."
02/01/2002 - "Pyrazine diazohydroxide (PZDH) is a new agent inhibiting DNA synthesis that is active in mouse tumor models and human xenografts and lacks cross resistance with multiple standard agents. "

04/01/1998 - "Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer."

01/01/1998 - "Phase II trial of pyrazine diazohydroxide in androgen-independent prostate cancer."

02/01/2002 - "Pyrazine diazohydroxide by this dose and schedule has insufficient activity in the treatment of disseminated malignant melanoma to warrant further investigation."
02/01/2002 - "A phase II trial of pyrazine diazohydroxide in patients with disseminated malignant melanoma and no prior chemotherapy--Southwest Oncology Group study."

08/01/2000 - "Phase II study of pyrazine diazohydroxide (NSC 361456) for advanced non small-cell lung cancer."